Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 1:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 522 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus Type 1 and 2 Clear all
Completed Not applicable Interventional Results available

Study to Compare Efficacy of the MiniMed Paradigm REAL-Time System Vs. MDI in Subjects Naive to Insulin Pump Therapy

NCT00417989
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
MiniMed Paradigm REAL-Time System
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
7 Years to 70 Years
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
26
States / cities
La Jolla, California • Orange, California • Boulder, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 8, 2026, 1:39 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

NCT05267626
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
Interventions
AU-007, Aldesleukin, Avelumab, Nivolumab
Drug
Lead sponsor
Aulos Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Miami, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

NCT06132126
View directory record Official record
Conditions
Healthy, Type 2 Diabetes Mellitus
Interventions
LY3938577, Placebo, Insulin degludec
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Anaheim, California • Miami, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 8, 2026, 1:39 AM EDT
Recruiting Not applicable Interventional

Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes

NCT06046833
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Gastroparesis With Diabetes Mellitus
Interventions
FreeStyle Libre 3 continuous glucose monitoring sensor, Nutritional drink
Device · Other
Lead sponsor
Samita Garg
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 8, 2026, 1:39 AM EDT
Recruiting No phase listed Observational

NYSCF Scientific Discovery Biobank

NCT06203106
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Interventions
Biological Sample Collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
30 Days and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2045
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 8, 2026, 1:39 AM EDT
Recruiting Not applicable Interventional

Hydration Intervention to Decrease Side Effects Associated With GLP - 1 RA Therapy

NCT07641361
View directory record Official record
Conditions
Obesity & Overweight, Type 2 Diabetes, Type 2 Diabetes (Adult Onset), Obesity Type 2 Diabetes Mellitus, Dehydration
Interventions
Hydration Plus, Control
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 8, 2026, 1:39 AM EDT
Not listed Not applicable Interventional

Improving Diabetes Equity and Advancing Care Study

NCT06040463
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Diabetes Self-Management Training (DSMT), Remote Glucose Monitoring (RGM), Community Health Worker tailored support
Behavioral
Lead sponsor
Sinai Health System
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Oct 8, 2026, 1:39 AM EDT
Not listed Not applicable Interventional

Exploratory Study of the Efficacy of Standard of Care Revascularization of the Lower Extremity

NCT04720170
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Revascularization
Procedure
Lead sponsor
Diabetes and Glandular Disease Clinic
Industry
Eligibility
30 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Phase 1 Interventional

A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 Diabetics

NCT01147861
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK256073, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
20 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Anniston, Alabama • Miami, Florida • Miami Gardens, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 8, 2026, 1:39 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Community Models for Hypertension and Diabetes Care for Refugees

NCT04229667
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Comorbidities and Coexisting Conditions
Interventions
Improved Community Health Volunteer (CHV) program
Other
Lead sponsor
International Rescue Committee
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2

NCT00574639
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Alprazolam, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 8, 2026, 1:39 AM EDT
Not yet recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.

NCT06731075
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
ORMD-0801 8 mg, Placebo capsule, ORMD-0801 16 mg
Drug · Other
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
50 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 8, 2026, 1:39 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus

NCT07160257
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Maridebart cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Phase 3 Interventional Results available

Naturlose (D-Tagatose) Efficacy Evaluation Trial

NCT00955747
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Tagatose, Sugar Substitute Splenda
Drug
Lead sponsor
Robert Lodder
Industry
Eligibility
18 Years to 75 Years
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
21
States / cities
Hueytown, Alabama • Huntsville, Alabama • Jonesboro, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Oct 8, 2026, 1:39 AM EDT
Completed No phase listed Observational

Blood Factors and Diabetic Retinopathy

NCT00005761
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
10 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Not applicable Interventional

Breakfast Nutrition and Inpatient Glycemia

NCT01805414
View directory record Official record
Conditions
Diabetes, Type 1, Diabetes, Type 2, Cardiovascular Disease, Hyperglycemia
Interventions
Modified Carbohydrate Breakfast, Control Breakfast
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 8, 2026, 1:39 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus

NCT04678557
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
VC-01 Combination Product
Combination Product
Lead sponsor
ViaCyte
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Escondido, California • Walnut Creek, California • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Not applicable Interventional

Resilient, Empowered, Active Living: REAL Diabetes Study

NCT02214641
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Resilient, Empowered, Active Living with Diabetes, Information Control
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 30 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Phase 2 Interventional

A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.

NCT00366379
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
GK Activator (2)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
10
States / cities
Chandler, Arizona • Oviedo, Florida • Nampa, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 8, 2026, 1:39 AM EDT
Terminated Phase 3 Interventional

A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients

NCT00391196
View directory record Official record
Conditions
Obesity
Interventions
Placebo, CP-945,598, CP-945,598 Treatment B
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
975 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
43
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2012 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Results available

4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes

NCT03538743
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Placebo, PF-06882961
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Anaheim, California • South Miami, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)

NCT03170544
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
MK-1092, 4.0 nmol/kg, MK-1092, 8.0 nmol/kg, MK-1092, 16 nmol/kg, MK-1092, 32 nmol/kg, MK-1092, 64 nmol/kg, Glargine 3.0 nmol/kg, Lispro 1.2 nmol/kg, Placebo to glargine, Placebo to MK-1092, Dextrose, Insulin
Drug · Other · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 8, 2026, 1:39 AM EDT
Recruiting Not applicable Interventional

Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery

NCT07011147
View directory record Official record
Conditions
Type 1 Diabetes (T1D), Type 2 Diabetes, Diabetes, Autoimmune, Diabetes Mellitus, Diabetes Mellitus Type 2, Diabetes Mellitus, Type I, Diabetes, Type II, Diabetes, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus Type II, Diabetes Type 2 on Insulin
Interventions
Bionic Pancreas, Routine Care
Device · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Phase 3 Interventional Results available

Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD

NCT01754259
View directory record Official record
Conditions
Diabetes, Type I, Diabetes, Type II, Angina, Coronary Artery Disease
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Oct 8, 2026, 1:39 AM EDT